Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 7325

Drug Profile

AZD 7325

Alternative Names: AZ-7325; AZD-7325

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; University College London
  • Developer AstraZeneca; Kings College London; University College London
  • Class Anxiolytics; Neuroprotectants; Nootropics
  • Mechanism of Action GABA A alpha 2 receptor modulators; GABA A alpha 3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neurological disorders; Pervasive child development disorders
  • Discontinued Anxiety disorders

Most Recent Events

  • 24 Sep 2018 Phase-I clinical trials in Pervasive child development disorders (In adults) in United Kingdom (PO) (NCT02530580)
  • 09 May 2017 Children's Hospital Medical Center plans a phase I trial for Fragile X syndrome in USA (NCT03140813)
  • 23 Jul 2015 Preclinical trials in Neurological disorders in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top